en.Wedoany.com Reported - Delonix Bioworks, a clinical-stage biotechnology company based in Shanghai, China, focusing on the development of genetically engineered bacterial vaccines, recently announced the initiation of the first-in-human dosing trial for its Group B meningococcal vaccine candidate, DX-104, in Perth, Australia. This Phase I clinical trial marks DX-104's entry into a critical development stage, aiming to evaluate its safety and immunogenicity in healthy adults.

The Phase I trial employs a randomized, double-blind, positive-controlled design and is currently underway in Perth, Australia. Following the completion of initial safety assessments and confirmation of safety, the study has proceeded as planned into a broader participant recruitment phase. DX-104 is an innovative Group B meningococcal vaccine developed based on Delonix Bioworks' proprietary OMV Plus™ platform, which is designed to optimize vaccine efficacy and safety.

Dr. Lin Qiubin, Founder and CEO of Delonix Bioworks, stated: "Initiating this Phase I trial is a significant milestone for Delonix Bioworks. Beyond advancing the Group B meningococcal vaccine program, this study also provides critical clinical validation for the OMV Plus™ platform. We are accelerating our OMV technology-based R&D pipeline, including vaccines targeting pertussis, Neisseria gonorrhoeae, and Klebsiella pneumoniae, to address the global challenge of antimicrobial resistance."

This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com